<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A total of 34 <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> samples (17 clinical samples and 17 cell lines) were analyzed for mutations of the Smad2 gene by reverse transcriptase-polymerase chain reaction single strand conformation polymorphism (RT-PCR-SSCP) analysis </plain></SENT>
<SENT sid="1" pm="."><plain>Nine of the 34 samples had 18q chromosomal abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>No shifted bands were detected in any of the <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Our results suggest that resistance to cell growth inhibitory effects of TGF-beta in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> is not due to alterations of the Smad2 gene </plain></SENT>
</text></document>